Not only in bladder cancer, G6PD was also overexpressed in colorectal cancer (CRC) cells, and high expression correlated with poor prognosis and poor outcome of oxaliplatin-based first-line chemotherapy in patients with CRC [27]. This evidence concerns the gene G6PD and urinary bladder carcinoma.